Proton-pump inhibitor-responsive esophageal eosinophilia

Current Opinion in Gastroenterology

Volumn 30, Issue 4, 2014, Pages 428-433

  Molina Infante, Javier ^a   Katzka, David A ^b  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b MAYO CLINIC   (United States)

Author keywords

Eosinophilic esophagitis; Gastroesophageal reflux disease; Proton pump inhibitor responsive esophageal eosinophilia

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT DISEASE; ANTIINFLAMMATORY ACTIVITY; CHILDHOOD DISEASE; DRUG EFFECT; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROSPECTIVE STUDY; PROTON PUMP INHIBITOR RESPONSIVE ESOPHAGEAL EOSINOPHILIA; RETROSPECTIVE STUDY; REVIEW; THERAPY EFFECT; ESOPHAGOSCOPY; PATHOLOGY; TREATMENT OUTCOME;

EOSINOPHILIC ESOPHAGITIS; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMANS; PHENOTYPE; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 84902264299     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000080     Document Type: Review

References (29)

1. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133:1342-1363.
2. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus: peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006; 101:1666-1670.
3. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007; 102:1301-1306.
4. Molina-Infante J, Ferrando-Lamana A, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011; 9:110-117.
5. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allerg Clin Immunol 2011; 128:3-10.
6. DellonES,Gonsalves N, Hirano I, et al.ACGclinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013; 108:679-692.
7. Molina-Infante J, Katzka DA, Gisbert JP. Review article: proton pump inhibitor therapy for suspected eosinophilic esophagitis. Aliment Pharmacol Ther 2013; 37:1157-1164.
8. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: A prospective cohort study. Am J Gastroenterol 2013; 108:1854-1860.
9. Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther 2013; 38:1312-1319.
10. Martinek J, Strosova A, Stefanova M, et al. Treatment with proton pump inhibitors is effective in a majority of adults patients with eosinophilic esophagitis. Gastroenterology 2013; 144 (Suppl 1); S-493.
11. Molina-Infante J, Rivas MD, Vinagre-Rodriguez G, et al. Remission in proton pump inhibitor-responsive esophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines, similarly to eosinophilic esophagitis after steroids. Gastroenterology 2013; 144 (Suppl 1); S-484.
12. Molina-Infante J, Gisbert JP. Letter: PPI-responsive esophageal eosinophilia: From initial sceptism to consistent prospective data. Aliment Pharmacol Ther 2014; 39:229-230.
13. Schroeder S, Capocelli KE, Masterson JC, et al. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2013; 56:166-172.
14. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012; 57:1413-1419.
15. Tomomatsu Y, Yoshino J, Inui K, et al. Clinical features of eosinophilic esophagitis: ten Japanese cases. Dig Endosc 2013; 25:117-124.
16. Abe Y, Iijima K, Ohara S, et al. A Japanese case series of 12 patients with esophageal eosinophilia. J Gastroenterol 2011; 46:25-30.
17. Fujiwara Y, Sugawa T, Tanaka F, et al. A multicenter study on the prevalence of eosinophilic esophagitis and PPI-responsive esophageal eosinophilic infiltration. Intern Med 2012; 51:3235-3239.
18. Moawad FJ, Schoepfer A, Mazer RA, et al. Eosinophilic esophagitis and proton pump inhibitor responsive esophageal eosinophilia: Are they one and the same? Gastroenterology 2013; 144 (Suppl 1):S-489.
19. Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology 2013; 145:1289-1299.
20. Tobey NA, Hosseini SS, Argote CM, et al. Dilated intercellular spaces and shunt permeability in nonerosive acid-damaged esophageal epithelium. Am J Gastroenterol 2004; 99:13-22.
21. Caviglia R, Ribolsi M, Gentile M, et al. Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with nonerosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25:629-636.
22. Farré R, Fornari F, Blondeau K, et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal nonexposed human oesophagus. Gut 2010; 59:164-169.
23. van Rhjin BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with PPI-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
24. Shouza RF, Huo X, Vittal M, et al. Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 2009; 137:1776-1784.
25. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut 2013; 62:824-832.
26. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: A review and discussion of the clinical implications. Dig Dis Sci 2009; 54:2312-2317.
27. Cortes JR, Rivas MD, Molina-Infante J, et al. Omeprazole inhibits IL-4 and IL-13 signaling signal transducer and activator of transcription 6 activation and reduces lung inflammation in murine asthma. J Allergy Clin Immunol 2009; 124:607-610.
28. Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012; 7:e50037.
29. Cheng E, Zhang X, Zhang Q, et al. TH2 cytokines stimulate eotaxin-3 secretion by esophageal fibroblasts: An effect that is not blocked by omeprazole. Gastroenterology 2013; 144 (Suppl 1):S79-80.